With three weeks until Strikeforce: Melendez vs. Healy in Sacramento, the promotion is starting to put together their next show on November 3rd. Heavyweights Daniel Cormier and Frank Mir now have a date set for the final Heavyweight bout under the Strikeforce banner as they will headline the Oklahoma City card.
When the fight was originally announced it was rumored to be on the above-mentioned September 29th card. Instead the former Oklahoma State University wrestling standout will have home field advantage for the biggest MMA fight of his career. Mir though is no stranger to fighting in his opponent’s backyard and will look to spoil the reunion. With both fighters immediately heading into the UFC heavyweight division following the bout, the winner will step right into the title picture.
Besides the main event, the Strikeforce: Cormier vs. Mir card will have a title fight as the co-main event. Middleweight champion Luke Rockhold will make his third title defense this year as he takes on Lorenz Larkin. Rockhold is coming off a unanimous decision win over Tim Kennedy in July after making his first defense with a first round TKO over Keith Jardine. Larkin has only fought once at middleweight once but the former light heavyweight look good in his decision win over the tough Robbie Lawler.
A great start to the fight card but Strikeforce wasn’t done, adding recently signed women’s bantamweight Sara McMann to make her promotional debut against Liz Carmouche. McMann has only been fighting in MMA since May of 2011 but the Olympic silver medallist is already 6-0 and is coming off a unanimous decision win over Shayna Baszler at Invicta FC 2. Carmouche is no stranger to Strikeforce, having fought for the bantamweight title before McMann even made her debut. With current bantamweight champion running out of arms to rip off, the winner could earn herself a shot at the title.
Strikeforce: Cormier vs Mir will take place from the Chesapeake Energy Arena in Oklahoma City, Oklahoma and will be televised on Showtime and Showtime Extreme.